AAP
GYRE icon

Arax Advisory Partners’s Gyre Therapeutics GYRE Stock Holding History

Arax Advisory Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62K Buy
+246
New +$1.68K ﹤0.01% 4858
2025
Q4 		– Sell
-57
Closed -$426 – 4276
2025
Q3 		$426 Buy
+57
New +$433 ﹤0.01% 3382

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Arax Advisory Partners's GYRE Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Gyre Therapeutics (GYRE) in Q2 2026: 246 shares worth $1.62K. The stake represents ﹤0.01% of the portfolio and ranks #4858 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in GYRE as recently as Q3 2025.

Arax Advisory Partners first reported a position in GYRE in Q3 2025 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Arax Advisory Partners held 246 shares of Gyre Therapeutics worth $1.62K as of Q2 2026.
  • Gyre Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Gyre Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4858 holding.
  • Arax Advisory Partners first reported a position in Gyre Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.